EyePoint EYPT
NASDAQ EYPT
$4.58 +0.01 (+0.33%)
As of: Sep 4, 2026 · 3:59 PM EDT

EyePoint (EYPT) Non Operating Interest Expenses (2018 - 2024)

Analysis

EyePoint (EYPT) Non Operating Interest Expenses (2018 - 2024) Analysis & Trends

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr) Non Operating Interest Expenses (Qtr)
1 Vertex Pharmaceuticals 138.47 Bn 130.62 Bn 2.84 Bn -
2 Regeneron Pharmaceuticals 85.18 Bn 77.19 Bn 3.93 Bn 11.00 Mn
3 Argenx Se 63.38 Bn 58.19 Bn 1.37 Bn -1.00 Mn
4 Moderna 58.09 Bn 52.95 Bn 52.00 Mn -
5 Revolution Medicines 44.33 Bn 44.33 Bn - 23.78 Mn
6 BeOne Medicines 40.02 Bn 34.92 Bn 1.53 Bn 39.74 Mn
7 Alnylam Pharmaceuticals 35.57 Bn 32.27 Bn 992.69 Mn 82.05 Mn
8 Royalty Pharma 28.45 Bn 27.61 Bn - 93.62 Mn
9 Insmed 27.48 Bn 26.32 Bn 358.27 Mn 20.27 Mn
10 EyePoint 398.53 Mn 218.06 Mn 507,000.00 -
Historic Data

Historic Data

Download Data
DateValue
Dec 31, 2024 14,000.00
Jun 30, 2023 435,000.00
Mar 31, 2023 812,000.00
Dec 31, 2022 781,000.00
Sep 30, 2022 662,000.00
Jun 30, 2022 552,000.00
Mar 31, 2022 1.19 Mn
Dec 31, 2021 1.39 Mn
Sep 30, 2021 1.39 Mn
Jun 30, 2021 1.38 Mn
Mar 31, 2021 1.35 Mn
Dec 31, 2020 1.83 Mn
Sep 30, 2020 1.84 Mn
Jun 30, 2020 1.81 Mn
Mar 31, 2020 1.78 Mn
Dec 31, 2019 1.79 Mn
Sep 30, 2019 1.77 Mn
Jun 30, 2019 1.60 Mn
Mar 31, 2019 1.02 Mn
Dec 31, 2018 1.64 Mn